Is Cytek Biosciences, Inc. (CTKB) Halal?

NASDAQ Healthcare United States $555M
✗ NOT HALAL
Confidence: 90/100
Cytek Biosciences, Inc. (CTKB) is Not Halal under AAOIFI Standard 21. While the debt ratio of 4.4% is acceptable, the cash and interest-bearing securities ratio of 48.2% exceeds the 30% threshold. Cytek Biosciences, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 4.4%
/ 30%
48.2%
/ 30%
13.3%
/ 30%
1.1%
/ 5%
✗ NOT HALAL
DJIM 4.4%
/ 33%
48.2%
/ 33%
13.3%
/ 33%
1.1%
/ 5%
✗ NOT HALAL
MSCI 5.1%
/ 33%
56.7%
/ 33%
15.6%
/ 33%
1.1%
/ 5%
✗ NOT HALAL
S&P 4.4%
/ 33%
48.2%
/ 33%
13.3%
/ 33%
1.1%
/ 5%
✗ NOT HALAL
FTSE 5.1%
/ 33%
56.7%
/ 33%
15.6%
/ 50%
1.1%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.52
P/B Ratio
1.6
EV/EBITDA
-9.7
EV: $318M
Revenue
$201M
Growth: 8.1%
Beta
1.3
High volatility
Current Ratio
5.0

Profitability

Gross Margin 51.8%
Operating Margin -9.0%
Net Margin -33.0%
Return on Equity (ROE) -18.0%
Return on Assets (ROA) -5.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$5M
Free Cash Flow-$9M
Total Debt$24M
Debt-to-Equity6.9
Current Ratio5.0
Total Assets$462M

Price & Trading

Last Close$4.58
50-Day MA$4.60
200-Day MA$4.30
Avg Volume839K
Beta1.3
52-Week Range
$2.37
$6.18

About Cytek Biosciences, Inc. (CTKB)

CEO
Dr. Wenbin Jiang Ph.D.
Employees
702
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap
$555M
Currency
USD

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Cytek Biosciences, Inc. (CTKB) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cytek Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Cytek Biosciences, Inc.'s debt ratio?

Cytek Biosciences, Inc.'s debt ratio is 4.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.1%.

What are Cytek Biosciences, Inc.'s key financial metrics?

Cytek Biosciences, Inc. has a market capitalization of $555M, and revenue of $201M. The company maintains a gross margin of 51.8% and a net margin of -33.0%. Return on equity stands at -18.0%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.